FLT3 and acute myeloid leukemia: The upregulation of UBE2L6 was enhanced by combination therapy using gilteritinib and HHT, and this may be the mechanism behind how the combination of gilteritinib and HHT exhibited a substantial antileukemic action on FLT3-ITD mutant AML cell lines.